دورية أكاديمية
Control of refractory hypercalcemia with denosumab in a case of metastatic parathyroid carcinoma
| العنوان: | Control of refractory hypercalcemia with denosumab in a case of metastatic parathyroid carcinoma |
|---|---|
| المؤلفون: | Çalapkulu, Murat |
| المساهمون: | Bursa Uludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji ve Metabolizma Anabilim Dalı., Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı., Bursa Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı., Gül, Özen Öz, Cander, Soner, Ersoy, Canan Özyardımcı, Ertürk, Erdinç, Sağıroğlu, Muhammed Fatih, Saraydaroğlu, Özlem, AAJ-6536-2021, AAH-8861-2021, AAH-9701-2021, AAI-1005-2021, CJH-1319-2022, DPC-0292-2022, 26040787100, 25027068600, 6701485882, 7005488796, 57218578082, 15074395500 |
| بيانات النشر: | College of Physicians and Surgeons Pakistan |
| سنة النشر: | 2019 |
| المجموعة: | Açık Erişim@BUU (Bursa Uludağ Üniversitesi) |
| مصطلحات موضوعية: | Parathyroid carcinoma, Denosumab, Hypercalcemia, Hyperparathyroidism, Management, General & internal medicine, Bone density conservation agents, Diphosphonates, Parathyroid hormone, Parathyroid neoplasms, Medicine, general & internal, Cancer, Primary Hyperparathyroidism, Alkaline phosphatase, Calcium, Cinacalcet, Creatinine, Furosemide, Phosphorus, Zoledronic acid, Bisphosphonic acid derivative, Bone density conservation agent, Adult, Alkaline phosphatase blood level, Article, Bone metastasis, Bone scintiscanning, Calcium blood level, Cancer recurrence |
| الوصف: | Parathyroid carcinoma is a rare cause of hyperparathyroidism and leads to severe hypercalcemia. The etiology is not fully known. Parathyroid cancer should be considered in the differential diagnosis, if serum calcium and parathyroid hormone levels increase, and parathyroid gland is palpable. Severe hypercalcemia is the most common cause of death in patients diagnosed with parathyroid carcinoma. Fluid replacement, diuretic therapy, bisphosphonates, and calcimimetic agents are the main treatment steps in the control of life-threatening hypercalcemia. Surgery is the primary treatment option, while denosumab is a treatment option for refractory hypercalcemia caused by parathyroid carcinoma, or for patients who are not eligible for surgery. There are few case reports in literature about denosumab treatment for parathyroid carcinoma. Herein, we report a case of a patient who presented with the complaint of leg pain and was diagnosed with parathyroid carcinoma. The elevated calcium level of the patient was controlled with denosumab. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1022-386X 1681-7168 |
| العلاقة: | Makale - Uluslararası Hakemli Dergi; JCPSP-Journal of the College of Physicians and Surgeons Pakistan; Yurt içi; Çalapkulu, M. vd. (2020). ''Control of refractory hypercalcemia with denosumab in a case of metastatic parathyroid carcinoma''. JCPSP-Journal of the College of Physicians and Surgeons Pakistan, 30(7), 757-759.; https://jcpsp.pk/article-detail/control-of-refractory-hypercalcemia-with-denosumab-in-a-case-of-metastatic-parathyroid-carcinomaTest; https://hdl.handle.net/11452/39402Test; 000561256500026; 2-s2.0-85089640645; 757; 759; 30; https://doi.org/10.29271/jcpsp.2020.07.757Test |
| DOI: | 10.29271/jcpsp.2020.07.757 |
| الإتاحة: | https://doi.org/10.29271/jcpsp.2020.07.757Test https://hdl.handle.net/11452/39402Test https://jcpsp.pk/article-detail/control-of-refractory-hypercalcemia-with-denosumab-in-a-case-of-metastatic-parathyroid-carcinomaTest |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.6F982DDE |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 1022386X 16817168 |
|---|---|
| DOI: | 10.29271/jcpsp.2020.07.757 |